TOL 101

Drug Profile

TOL 101

Alternative Names: TOL-101

Latest Information Update: 23 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Cleveland Clinic Foundation
  • Developer Tolera Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection; Type 1 diabetes mellitus
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 23 Sep 2015 No recent reports on development identified - Phase-I/II for Transplant rejection (Prevention) in USA (IV)
  • 23 Sep 2015 No recent reports on development identified - Preclinical for Type-1 diabetes mellitus in USA (unspecified route)
  • 16 Oct 2012 TOL 101 is still in phase I/II trials for Transplant rejection (prevention) in US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top